We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study.
- Authors
Delgado, Mauricio R; Tilton, Ann; Carranza‐Del Río, Jorge; Dursun, Nigar; Bonikowski, Marcin; Aydin, Resa; Maciag‐Tymecka, Iwona; Oleszek, Joyce; Dabrowski, Edward; Grandoulier, Anne‐Sophie; Picaut, Philippe; Renders, Anne; Kraus, Josef; Minks, Eduard; Givon, Uri; Sadaka, Yair; Weigl, Daniel; Fattal‐Valevski, Aviva; Ben‐Pazi, Hilla; Gonzalez, Jose Alberto Moreno
- Abstract
Aim: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). Method: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home‐exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. Results: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment‐related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). Interpretation: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. What this paper adds: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy.Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment.Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises.AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year. What this paper adds: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy.Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment.Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises.AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year. This article is commented on by Graham on page 499 of this issue. This article's abstract has been translated into Spanish and Portuguese. Follow the links from the abstract to view the translations.
- Subjects
CHILDREN with cerebral palsy; DRUG efficacy; SPASTICITY; ADVERSE health care events; INJECTIONS
- Publication
Developmental Medicine & Child Neurology, 2021, Vol 63, Issue 5, p592
- ISSN
0012-1622
- Publication type
Article
- DOI
10.1111/dmcn.14733